Results 261 to 270 of about 149,070 (296)

Posttransplant MRD monitoring by TP53 duplex sequencing with APR-246 + azacitidine maintenance predicts outcomes. [PDF]

open access: yesBlood Adv
Sallman DA   +15 more
europepmc   +1 more source

Somatic and germline genetic testing pathways in haematological malignancies: Best practice consensus guidelines from the 2025 national meeting organised by UK Cancer Genetics Group (UKCGG), CanGene‐CanVar and the NHS England Haematological Oncology Working Group

open access: yesBritish Journal of Haematology, EarlyView.
Summary Genomic technologies including next‐generation sequencing (NGS) and arrays for cytogenetic anomalies are now standard of care in England for the diagnostic evaluation of patients with suspected haematological malignancies. Challenges remain in the management of potential germline findings as a result of NGS panels and copy number variant ...
B. Speight   +12 more
wiley   +1 more source

Intermittent fasting inhibits Tp53-driven glioma through gut microbiota-mediated methionine-m<sup>6</sup>A regulation. [PDF]

open access: yesNat Commun
Lin Y   +19 more
europepmc   +1 more source

Leveraging paired germline and somatic analysis to improve the classification of DDX41 variants

open access: yesBritish Journal of Haematology, EarlyView.
Summary Constitutional pathogenic variants in DDX41 predispose to myelodysplasia and acute myeloid leukaemia. Acquisition of subsequent somatic hits in the second allele is frequent, with notable recurrent variants at key hotspots. Sequencing of Deoxyribonucleic acid from blood/marrow of 239 patients with suspected/confirmed haematological malignancies
Andrew George   +13 more
wiley   +1 more source

Tumor suppressor genes in the tumor microenvironment

open access: yesDisease Models & Mechanisms
Bahareh Tabanifar   +2 more
doaj   +1 more source

Mosaic Li Fraumeni Syndrome Not Identified in Germinal Tissue. [PDF]

open access: yesMol Genet Genomic Med
Urban RM   +9 more
europepmc   +1 more source

Prediction Analysis of Microarray of 50 genes (PAM50) classifier validated for predicting prostate cancer progression in active surveillance: Miami Active Surveillance Trial (MAST)

open access: yesBJU International, EarlyView.
Objectives To evaluate basal‐luminal cell of origin subtyping using Prediction Analysis of Microarray of 50 genes (PAM50) genomic classification profiles for predicting disease progression in men undergoing active surveillance (AS) for prostate cancer (PCa).
Ankur Malpani   +24 more
wiley   +1 more source

Home - About - Disclaimer - Privacy